【24h】

Percutaneous Pulmonary Valve Implantation

机译:经皮肺动脉瓣植入

获取原文
获取原文并翻译 | 示例
           

摘要

Percutaneous pulmonary valve implantation is a new treatment option in patients with dysfunctional conduits. The aim of percutaneous pulmonary valve implantation is to prolong the lifespan of right ventricle to pulmonary artery conduits and thereby postponing open-heart surgery. Early results have shown a significant reduction in right ventricular pressure and right ventricular outflow tract gradient. During a follow-up of a median of 28 months, freedom from re-operation is 93 (2), 86 (3), 84 (4), and 70 (13)% at 10, 30, 50, and 70 months, respectively. The most common complication during follow-up are stent fractures with an incidence around 20%. Although clinically silent in the majority of cases, stent fractures led to re-intervention in the form of implantation of a second device (valve-in-valve). Valvar function during follow-up was well maintained. Significant pulmonary regurgitation was only seen in the context of endocarditis. Pulmonary valve implantation has the potential to become the standard procedure in the treatment of dysfunctional conduits. Bigger challenges will now have to be met in order to extend this technology to patients with native outflow tracts and free pulmonary regurgitation.
机译:经皮肺动脉瓣植入术是导管功能不全患者的新治疗选择。经皮肺动脉瓣植入的目的是延长右心室到肺动脉导管的寿命,从而推迟心脏直视手术。早期结果显示右心室压力和右心室流出道梯度显着降低。在平均28个月的随访期间,在10、30、50和70个月时,再次手术的自由度分别为93(2),86(3),84(4)和70(13)%,分别。随访期间最常见的并发症是支架骨折,发生率约20%。尽管在大多数情况下临床上无声,但支架骨折导致以第二种设备(瓣膜中瓣膜)的植入形式再次介入。随访期间的瓦尔瓦尔功能得到了很好的维持。仅在心内膜炎的情况下才出现明显的肺返流。肺动脉瓣植入术有可能成为功能障碍导管治疗的标准程序。为了将这项技术扩展到具有自然流出道和自由肺关闭不全的患者,现在将不得不面对更大的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号